A recent study presented at the American College of Rheumatology (ACR) 2025 Annual Meeting has revealed a promising link between GLP-1 receptor agonists—a class of drugs commonly prescribed for diabetes and weight management—and a reduction in rheumatoid arthritis (RA) flares. Researchers observed that patients using GLP-1 therapies experienced fewer inflammatory episodes, improved mobility, and better overall disease control compared to those on standard treatment alone.